This study aimed to assess the cost-effectiveness of insulin glargine/lixisenatide (iGlarLixi) in comparison with premixed insulin for patients with basal insulin-uncontrolled type 2 diabetes in South Korea. The CORE Diabetes Model, a Markov model, was used with the following settings: a 30 year horizon, a payer perspective, and a 3% discount rate. Each treatment was assumed to be administered for the first 3 years, and then switched to rescue regimen. The baseline HbA1c and body mass index (BMI) were 8.6 ± 1.3%, and 24.4 ± 3.3 kg/m2, respectively. Indirect treatment comparisons showed that iGlarLixi resulted in significantly greater reduction from baselines for HbA1c and BMI compared with premixed insulin; −0.50% (95% confidence interval (CI): −0.68, −0.32) for HbA1c and −0.80 kg/m2 (95% CI: −1.29, −0.31) for BMI. In the base analysis, iGlarLixi was found to be dominant (more effective and less costly) over premixed insulin with 0.079 additional quality-adjusted life-years and lowered cost by approximately 230 USD, and the incremental costutility ratios from sensitivity analyses also remained dominant or below 10,000 USD. This study demonstrated that iGlarLixi was cost effective for treating patients with type 2 diabetes with poor glucose control on basal insulin in comparison with premixed insulin in South Korea.
Introduction
Experimental Methods
Experimental Results
Discussion
Acknowledgment
Conflict of Interest
References